Denosumab is indicated for treating osteoporosis in postmenopausal women, preventing skeletal-related complications in cancer ...

Majestic Research Study Indicates Physicians Are Enthusiastic about Prolia’s Infrequent Dosing Regimen, but Have Concerns about the High Cost of Therapy However, physicians did express concerns about ...

Denosumab is a monoclonal antibody that inhibits bone resorption and is widely used across oncology and osteoporosis-related ...

The US Food and Drug Administration (:FDA) recently granted approval to Amgen’s (AMGN) Prolia (denosumab) for an additional indication. Prolia can now be used as a treatment for increasing bone mass ...

THOUSAND OAKS, Calif., Nov. 5, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive data from the first three years of the open-label extension study of the pivotal Phase 3 fracture ...

Amneal wins FDA approval for two denosumab biosimilars, expanding lower-cost treatment options for bone loss and cancer patients.

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive topline results from a ...

Prolia (denosumab) is a medication for osteoporosis. A healthcare professional administers Prolia via injection under the skin every 6 months. Medicare covers Prolia for beneficiaries. Since a ...

Dr. Keith Roach writes a medical question-and-answer column weekdays. Dear Dr. Roach: My wife’s doctor wants her to start Prolia shots for bone density, but the reviews I have been reading are ...

The US Food and Drug Administration (FDA) issued an alert today that cited preliminary evidence for a "substantial risk" for severe and symptomatic hypocalcemia and serious outcomes related to ...

THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced new long-term data showing that during the fourth and fifth years of Prolia® (denosumab) treatment, ...